APELLIS PHARMACTDL (Germany) Today
| 1JK Stock | EUR 27.24 1.35 4.72% |
Performance1 of 100
| Odds Of DistressLess than 29
|
APELLIS PHARMACTDL is trading at 27.24 as of the 4th of February 2025. This is a 4.72% down since the beginning of the trading day. The stock's lowest day price was 27.24. APELLIS PHARMACTDL has about a 29 % chance of experiencing some form of financial distress in the next two years of operation and did not have a very good performance during the last 90 trading days. The performance scores are derived for the period starting the 5th of January 2025 and ending today, the 4th of February 2025. Click here to learn more.
Apellis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts. The company has 110.58 M outstanding shares. More on APELLIS PHARMACTDL 0001
Moving against APELLIS Stock
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
APELLIS Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. APELLIS PHARMACTDL's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding APELLIS PHARMACTDL or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| CEO | Cedric Francois |
| Business Concentration | Biotechnology, Healthcare (View all Sectors) |
APELLIS PHARMACTDL 0001 (1JK) is traded on Frankfurt Exchange in Germany and employs 767 people. The company currently falls under 'Mid-Cap' category with a current market capitalization of 5.78 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate APELLIS PHARMACTDL's market, we take the total number of its shares issued and multiply it by APELLIS PHARMACTDL's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. APELLIS PHARMACTDL 0001 classifies itself under Healthcare sector and is part of Biotechnology industry. The entity has 110.58 M outstanding shares.
APELLIS PHARMACTDL 0001 has accumulated about 599.01 M in cash with (239.85 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 6.89.
Check APELLIS PHARMACTDL Probability Of Bankruptcy
Ownership AllocationAPELLIS PHARMACTDL holds a total of 110.58 Million outstanding shares. The majority of APELLIS PHARMACTDL 0001 outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in APELLIS PHARMACTDL 0001 to benefit from reduced commissions. Thereupon, institutional investors are subject to a different set of regulations than regular investors in APELLIS PHARMACTDL. Please pay attention to any change in the institutional holdings of APELLIS PHARMACTDL 0001 as this could imply that something significant has changed or is about to change at the company. Also note that nearly four million nine hundred fifty-three thousand eight hundred five invesors are currently shorting APELLIS PHARMACTDL expressing very little confidence in its future performance.
Check APELLIS Ownership Details
APELLIS PHARMACTDL 0001 Risk Profiles
Although APELLIS PHARMACTDL's alpha and beta are two of the key measurements used to evaluate APELLIS PHARMACTDL's performance over the market, the standard measures of volatility play an important role as well.
| Mean Deviation | 2.74 | |||
| Semi Deviation | 3.06 | |||
| Standard Deviation | 3.87 | |||
| Variance | 14.96 |
APELLIS Stock Against Markets
Be your own money manager
Our tools can tell you how much better you can do entering a position in APELLIS PHARMACTDL without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Equity Forecasting Now
Equity ForecastingUse basic forecasting models to generate price predictions and determine price momentum |
| All Next | Launch Module |
APELLIS PHARMACTDL Corporate Management
Elected by the shareholders, the APELLIS PHARMACTDL's board of directors comprises two types of representatives: APELLIS PHARMACTDL inside directors who are chosen from within the company, and outside directors, selected externally and held independent of APELLIS. The board's role is to monitor APELLIS PHARMACTDL's management team and ensure that shareholders' interests are well served. APELLIS PHARMACTDL's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, APELLIS PHARMACTDL's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Nicole Perry | Vice President - Finance | Profile | |
| Adam Townsend | Chief Commercial Officer | Profile | |
| Alec Machiels | Independent Director | Profile | |
| Thomas Lackner | Senior Vice President Head of Europe | Profile | |
| Paul Fonteyne | Independent Director | Profile | |
| A Dunlop | Independent Director | Profile |
Other Information on Investing in APELLIS Stock
APELLIS PHARMACTDL financial ratios help investors to determine whether APELLIS Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in APELLIS with respect to the benefits of owning APELLIS PHARMACTDL security.